Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics Continues to Build World Class Scientific Advisory Board with Appointment of Hector J. Gomez, MD, PhD
MINNEAPOLIS , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has appointed Dr. Hector J. Gomez , President & CEO, Co-Founder of GLG
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Signs International Distribution Agreement with India-based Prenit World
MINNEAPOLIS , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) is pleased to announce that its Skyline Medical division, producer of the FDA -approved and CE-marked  STREAMWAY® System  for automated, direct-to-drain medical fluid
View HTML
Toggle Summary Precision Therapeutics Secures First STREAMWAY System Sale in Europe
MINNEAPOLIS , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”) is pleased to announce it has secured its first European sale of the STREAMWAY System® , an automated, direct-to-drain medical fluid disposal system sold by the Company’s
View HTML
Toggle Summary Dr. Bob Murphy, Head of Computational Biology at Carnegie Mellon University, Joins Precision Therapeutics’ Scientific Advisory Board
MINNEAPOLIS , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has appointed Dr. Robert Murphy to its Scientific Advisory Board . Dr.
View HTML
Toggle Summary Precision Therapeutics Bolsters Scientific Advisory Board with the Appointment of Dr. Paul Kornblith
MINNEAPOLIS , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has bolstered its Scientific Advisory Board with the appointment of Dr.
View HTML
Toggle Summary Precision Therapeutics Appoints Dr. Amelia Warner to Scientific Advisory Board
MINNEAPOLIS , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Dr.
View HTML
Toggle Summary Precision Therapeutics Forms Scientific Advisory Board to Advance its Strategy in the Precision Medicine Sector
Marc Malandro PhD Named First Member of Scientific Advisory Board MINNEAPOLIS , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased
View HTML
Toggle Summary Precision Therapeutics Reports Second Quarter 2018 Financial Results
Helomics Holding Corporation, predicted to generate approximately $3.2 million in revenues by the end of 2018 MINNEAPOLIS , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to
View HTML
Toggle Summary Precision Therapeutics Investee, Helomics Corporation, Announces Commercial Launch of New ‘HelomicsDiscover’ Program to Drive Forward the Next Generation of Precision Cancer Therapies
MINNEAPOLIS , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Helomics Corporation , which has a definitive
View HTML
Toggle Summary Precision Therapeutics Investee, Helomics Corporation, Launches Precision Oncology Insights Platform
MINNEAPOLIS , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Helomics Corporation , which has a definitive
View HTML